A Food and Drug Administration panel of outside medical experts said a Bayer AG drug, used to control bleeding in patients undergoing heart-bypass surgery, should stay on the U.S. market.
When manipulation of the ascending aorta is planned, EAU is effective in guiding the surgical strategy to reduce the risk for embolic stroke in these patients.
